BrevaRex MAb targets the tumor associated antigen MUC1 and has successfully completed a Phase I safety and immunology study.
Additional findings for
BrevaRex MAb (under development for multiple myeloma), GivaRex Mab (under development for gastrointestinal cancers), and ProstaRex MAb (under development for prostate cancer) illustrate the importance of using a foreign antibody that complexes with a circulating TAA.
The Compnay's most advanced product, OvaRex MAb for ovarian cancer, is in two potentially pivotal Phase IIb clinical trials, while
BrevaRex MAb is in a Phase I study.
The company's most advanced product, OvaRex MAb for ovarian cancer, is in two potentially pivotal Phase IIb clinical trials, while
BrevaRex MAb has recently entered a Phase I study.